Video

Tara Vijayan, MD: Combating Drug Scarcity

Author(s):

High-risk individuals should be targeted when drug scarcity comes into play.

Drug scarcity are a major problem in medicine that was only exacerbated during the COVID-19 pandemic.

In fact, during the height of the pandemic when new and effective drugs to combat the virus were produced, drug scarcity involving these drugs was a huge issue.

With more and more patients being hospitalized with COVID-19, particularly in inner cities and minority communities, there was a need to disperse the drugs in a fair and equitable way.

In an interview with HCPLive®, Tara Vijayan, MD, assistant professor of medicine in the Division of Infectious Diseases and medical director of antimicrobial stewardship at the David Geffen School of Medicine at UCLA, explained some of the issues with drug scarcity and how exactly primary care physicians can combat this issue.

“This is an ongoing issue, not just with novel therapeutics, but with drugs that we’ve had for a long, long time,” Vijayan said. “Drug scarcity is going to be an ongoing issue and really prioritizing individuals who are at the highest risk is really important, both highest risk for progression and highest risk for exposure by virtue of being in certain communities that have lower access to certain resources.”

However, Vijayan did say that it has come a long way in this area and changes are beginning to take hold.

Vijayan recently gave a keynote address during Pri-Med West 2022 in Anaheim.

Related Videos
Jörn Schattenberg, MD | Credit: Novo Nordisk
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Jörn Schattenberg, MD | Credit: Novo Nordisk
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
How to Manage Aspirin-Exacerbated Respiratory Disease
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
© 2024 MJH Life Sciences

All rights reserved.